Wyatt Technology Announces Breakthrough in Field Flow Fractionation (FFF) Separation Technology

Wyatt Technology, the world leader in instrumentation for absolute macromolecular and nanoparticle characterization, reveals the launch of its 6thgeneration Eclipse™ FFF system that represents an entirely new paradigm of FFF technology

Wyatt Technology
Oct 23, 2020

This completely new line of separation instrumentation and software was designed for the widest range of analytes including proteins, polymers, viruses, gene vectors, liposomal drug nanoparticles, and more. Covering a range of sizes from 1 nm to 10 µm, the Eclipse offers programmable separation power for enhanced resolution within any size range. The system incorporates sophisticated micro-controllers and sensors with built-in intelligence and an intuitive interface to ensure simple use, reliability and repeatability across research, development and quality control environments. 

The introduction of Mobility™ implements electrical/asymmetric-flow FFF for determining size-resolved zeta potential. The new Dilution Control Module™ (DCM) increases sample concentrations up to 10x, for higher sensitivity and fraction titer. Improved channel design provides unique and accurate temperature control for higher sample recovery, reproducibility and pressure stability. 

Geofrey Wyatt, CEO of Wyatt Technology, said, “To say that I’m proud of the accomplishments of Team Wyatt in developing the new Eclipse and Mobility hardware products, and VISION software package would be an understatement. Add in the complexities of coordinating so many contributors during a pandemic and we have an extraordinary story on our hands. The complete execution of a product redesign is difficult enough under ordinary circumstances, but in this case it was re-imagining of what FFF is and how it can be made more accessible to more scientists. The resulting products, their novelty and their utility move FFF from a relatively obscure area of separation science into the mainstream.” 

Developing reliable means of separation and characterization methods is just one more way that Wyatt Technology fulfills its mission: to help ensure our customers’ success in providing leading-edge, life-enhancing products.

November 2020

Death on the shore

Researchers investigate recent gray whale strandings along North America’s Pacific coast


Sponsored Product Updates

Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.
The Rise of Cannabis Extraction Labs
Scientists in cannabis extraction laboratories are bravely pioneering a new field of agro-chemical engineering.
Expanding Cell Growth Capabilities
Download this eBook to learn how to optimize large-scale cell growth using culture shakers, incubators, and bioreactors!
SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients
SynDevRx has submitted to the FDA results from a Phase 1 dose escalation study in patients with metastatic and progressing solid tumors to assess the safety and tolerability of SDX-7320. Additional outcome measures suggest that SDX-7320 may slow the rate of disease progression and formation of new metastases. Exploratory endpoints suggest that SDX-7320 may induce favorable changes to insulin and insulin resistance and other key metabolic hormones (leptin, adiponectin) as well as to multiple angiogenic biomarkers.